Search DIAN Data Resource Requests

In order to avoid the situation where two investigators study the same research question, please search our database to determine if your topic has already been studied. If you find that your topic or a related topic has already been submitted, you may wish to contact the investigator to inquire about his/her findings to determine how you might proceed. You may wish to collaborate or modify your request to avoid overlap. The results below reflect requests made since online requests have been accepted. As such, not all fields will have data as certain information, such as aims, were not collected until recently. If an entry has been assigned an ID # (e.g. DIAN-D1004), the full request has been submitted and is either approved, disapproved or in process.

Displaying 21 - 30 of 238

Investigator:Anna Dieffenbacher

Title:Specific facets of Personality traits in Autosomal Dominant Alzheimer disease

Date of Request:08/30/2020

Aim 1:1) to determine the different baseline differences between mutation carriers and non-mutation carriers in respect to the facets within each Personality Factor (OCEAN: openness to experience, conscientiousness, extraversion, agreeableness, and neuroticism). 2) to analyze longitudinal changes of facets within mutation-carriers and non-carriers.

Investigator:Ronald Hawley


Date of Request:08/07/2020

Aim 1:test the form

Aim 2:test the form 2

Aim 3:test the form 3

Aim 4test the form 4

Investigator:Suman Jayadev

Title:Investigating microRNA and immune gene regulation in fAD gene carriers

Date of Request:07/30/2020

Aim 1:To determine if AD pathogenesis involves altered gene regulation of peripheral macrophage function, we will profile miRNA/mRNA expression in monocytes isolated from ADAD gene carriers or age-matched controls. We hypothesize that dysregulated peripheral immune cells in ADAD further contribute to disease. In collaboration with the Wash U DIAN site, we have collected CD14 cells from DIAN participants. We will use computational approaches to characterize the impact of ADAD mutations on peripheral cells. We include DIAN collected variables for analyses.

Investigator:Disha Shah

Title:Functional connectivity disruptions at early stages in Alzheimer’s Disease: a comparison of brain networks in mouse models and humans.

Date of Request:07/20/2020

Aim 1:We would like to access rsfMRI data from APP and PSEN1/2 carriers versus non carriers to compare functional connectivity disruptions in human AD with functional connectivity disruptions we observe in mouse models of Alzheimer's pathology. We would like to compare whether the same brain regions are involved, to study the extent to which our findings in mice can be translated to humans.


Title:Neurological examination findings in Alzheimer disease

Date of Request:06/22/2020

Aim 1:to determine a muster of neurological examination findings in AD and to investigate their prevalences over the disease course

Aim 2:evaluate the capability of neurological examinations findings in Alzheimer disease to distinguish mutation carriers from non mutation carriers among mildly cognitive symptomatic at risk individuals

Aim 3:to analyze cross-sectional and

Aim 4longitudinal associations between cognitive performance and neurological examination findings in Alzheimer disease

Investigator:Jeremy Strain

Title:Functional and Structural Correlates of Genetics in ADAD

Date of Request:06/15/2020

Aim 1:Does connectivity strength change based on APOE status or associate with the polygenetic risk score in an ADAD cohort.

Aim 2:Does structural connectivity change based on APOE status or associate with the polygenetic risk score in an ADAD cohort.

Aim 3:Does structural or functional connectivity temporally associate with proteomic data.


Title:Changes in personality in DIAN

Date of Request:05/08/2020

Aim 1:To evaluate the magnitude of within person personality change in DIAN.

Aim 2:To establish a causal link between personality change and AD biomarkers

Aim 3:Evaluate which specific “facets” of personality shown the most reliable change in preclinical ADAD.